Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| TOPAS | Other Identifier | Company Internal | |
| AX 0601 | Other Identifier | Company Internal | |
| 12867 - AX0601AT | Other Identifier | Company Internal | |
| 12868 - AX0601PK | Other Identifier | Company Internal | |
| 12869 - AX0601EG | Other Identifier | Company Internal | |
| 12870 - AX0601NL | Other Identifier | Company Internal | |
| 12973 - AX0601SK | Other Identifier | Company Internal | |
| 12974 - AX0601SG | Other Identifier | Company Internal | |
| 13026 - AX0601ID | Other Identifier | Company Internal | |
| 13046 - AX0601PH | Other Identifier | Company Internal | |
| 13111 - AX0601RO | Other Identifier | Company Internal | |
| 13065 - AX0601CN | Other Identifier | Company Internal | |
| 13207 - AX0601FR | Other Identifier | Company Internal | |
| 13166 - AX0601MY | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Avelox (Moxifloxacin, BAY12-8039) | Drug | Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of | Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days). |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of tolerability and safety of Avalox® in daily practice were investigated. | Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days). | |
| Patient characteristics in acute bacterial sinusitis | Documentation at baseline visit. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Austria | |||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23626752 | Derived | Mosges R, Desrosiers M, Arvis P, Heldner S. Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study. PLoS One. 2013 Apr 23;8(4):e61927. doi: 10.1371/journal.pone.0061927. Print 2013. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012852 | Sinusitis |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D010254 | Paranasal Sinus Diseases |
| D009668 | Nose Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
Not provided
Not provided
Not provided
Not provided
Not provided
| History and frequency of sinusitis episodes | Documentation at baseline visit. |
| Diagnostic procedures and therapeutic options chosen by physicians in daily practice | Documentation at baseline visit. |
| Many Locations |
| Bahrain |
| Many Locations | China |
| Many Locations | Egypt |
| Many Locations | France |
| Many Locations | Germany |
| Many Locations | Indonesia |
| Many Locations | Jordan |
| Many Locations | Kuwait |
| Many Locations | Lebanon |
| Many Locations | Malaysia |
| Many Locations | Netherlands |
| Many Locations | Pakistan |
| Many Locations | Philippines |
| Many Locations | Romania |
| Many Locations | Saudi Arabia |
| Many Locations | Singapore |
| Many Locations | United Arab Emirates |
| Many Locations | Yemen |
| D012140 |
| Respiratory Tract Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |